Kyverna Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$5.24

+1.53%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $5.16
Volume: 974,150
Day's high: —
Day's low: —

In brief

Kyverna Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $324M.
Its shares closed at $5.16 on 4 Nov 2026, down 18.9% over the past year.
From India you can buy KYTX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Kyverna Therapeutics, Inc. (KYTX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole KYTX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade KYTX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Set a 52-week low on 4 Nov 2026
Closed at $5.16 on 4 Nov 2026: 62.3% below the 52-week high of $13.67 (15 Dec 2025) and 2.8% above the low of $5.02 (4 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −16.2% (SPY −1.6%, XLV +13.5%). 3 months: −32.5% (SPY −0.4%, XLV +15.5%). 1 year: −18.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: KYTX, SPY and XLV · as of 4 Nov 2026
10.5 days to cover short interest
9.5M shares were sold short at the 15 Oct 2026 settlement, 15.4% of the 61.8M shares outstanding; covering them would take 10.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $5.16 was 23.1% below its 50-day average ($6.71) and 35.8% below its 200-day average ($8.04). It has closed below the 200-day for 44 sessions, since 3 Sep 2026. The 50-day average crossed below the 200-day on 28 Jul 2026, 70 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−16.2%

6 months−45.5%

1 year−18.9%

5 years—

Newswire

About

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Website

Notable moves

December 17, 2025
−32.52%
October 8, 2025
+32.72%
June 14, 2024
−34.00%

Kyverna Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$5.24

+1.53%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $5.16
Volume: 974,150
Day's high: —
Day's low: —

In brief

Kyverna Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $324M.
Its shares closed at $5.16 on 4 Nov 2026, down 18.9% over the past year.
From India you can buy KYTX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Kyverna Therapeutics, Inc. (KYTX) shares from India?

Do I need the price of a whole KYTX share to invest?

How much can I invest in US stocks in a year?

Can I trade KYTX options or futures?

Insights

Quotes run fifteen minutes behind.

Set a 52-week low on 4 Nov 2026
Closed at $5.16 on 4 Nov 2026: 62.3% below the 52-week high of $13.67 (15 Dec 2025) and 2.8% above the low of $5.02 (4 Nov 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −16.2% (SPY −1.6%, XLV +13.5%). 3 months: −32.5% (SPY −0.4%, XLV +15.5%). 1 year: −18.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: KYTX, SPY and XLV · as of 4 Nov 2026
10.5 days to cover short interest
9.5M shares were sold short at the 15 Oct 2026 settlement, 15.4% of the 61.8M shares outstanding; covering them would take 10.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $5.16 was 23.1% below its 50-day average ($6.71) and 35.8% below its 200-day average ($8.04). It has closed below the 200-day for 44 sessions, since 3 Sep 2026. The 50-day average crossed below the 200-day on 28 Jul 2026, 70 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−16.2%

6 months−45.5%

1 year−18.9%

5 years—

Newswire

About

Website

Notable moves

December 17, 2025
−32.52%
October 8, 2025
+32.72%
June 14, 2024
−34.00%

Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. in brief

Set a 52-week low on 4 Nov 2026

Behind SPY and its sector fund XLV over 1 year

10.5 days to cover short interest

Below its 50- and 200-day averages

Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. in brief

Set a 52-week low on 4 Nov 2026

Behind SPY and its sector fund XLV over 1 year

10.5 days to cover short interest

Below its 50- and 200-day averages